Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | The value of bispecifics in myeloma & the importance of optimizing the sequencing of these agents

Azra Borogovac, MD, City of Hope, Duarte, CA, discusses the value of bispecific antibodies, including teclistamab, talquetamab and elranatamab, in the treatment of multiple myeloma. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.